Bioprocessing and the Production of Antiviral Biologics in the Prevention and Treatment of Viral Infectious Disease
Vaccines · 17.05.2023 · 11 (5) · 992
DOI: 10.3390/vaccines11050992 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 17.05.2023. Verfasst von Elaine Meade und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Atlantic Technological University, F91 YW50 Sligo, Ireland. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Emerging, re-emerging and zoonotic viral pathogens represent a serious threat to human health, resulting in morbidity, mortality and potentially economic instability at a global scale. Certainly, the recent emergence of the novel SARS-CoV-2 virus (and its variants) highlighted the impact of such pathogens, with the pandemic creating unprecedented and continued demands for the accelerated production of antiviral therapeutics. With limited effective small molecule therapies available for metaphylaxis, vaccination programs have been the mainstay against virulent viral species. Traditional vaccines remain highly effective at providing high antibody titres, but are, however, slow to manufacture in times of emergency. The limitations of traditional vaccine modalities may be overcome by novel strategies, as outlined herein. To prevent future disease outbreaks, paradigm shift changes in manufacturing and distribution are necessary to advance the production of vaccines, monoclonal antibodies, cytokines and other antiviral therapies. Accelerated paths for antivirals have been made possible due to advances in bioprocessing, leading to the production of novel antiviral agents. This review outlines the role of bioprocessing in the production of biologics and advances in mitigating viral infectious disease. In an era of emerging viral diseases and the proliferation of antimicrobial resistance, this review provides insight into a significant method of antiviral agent production which is key to protecting public health.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Life Science, Atlantic Technological University, F91 YW50 Sligo, Ireland.
- Centre for Precision Engineering, Materials and Manufacturing Research (PEM), Atlantic Technological University, F91 YW50 Sligo, Ireland.
- Bioscience Research Institute, Technical University Shannon Midlands Midwest, N37 HD68 Athlone, Ireland.
ORCID-Profile: Neil Rowan, Mary Garvey
Zitieren
APA
Meade, E., Rowan, N., & Garvey, M. (2023). Bioprocessing and the Production of Antiviral Biologics in the Prevention and Treatment of Viral Infectious Disease. Vaccines, 11(5), 992. https://doi.org/10.3390/vaccines11050992
Vancouver
Meade E, Rowan N, Garvey M. Bioprocessing and the Production of Antiviral Biologics in the Prevention and Treatment of Viral Infectious Disease. Vaccines. 2023;11(5):992. doi:10.3390/vaccines11050992
BibTeX
@article{Meade2023,
author = {Meade, Elaine and Rowan, Neil and Garvey, Mary},
title = {Bioprocessing and the Production of Antiviral Biologics in the Prevention and Treatment of Viral Infectious Disease},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {5},
pages = {992},
doi = {10.3390/vaccines11050992}
}
EUVIMED